InvestorsHub Logo
icon url

JRoon71

04/19/22 11:01 AM

#375136 RE: mrmainstreet #375135

Good article, and reiterates what most of us know already. But it's nice to see it out there.
icon url

lizzy241

04/19/22 11:18 AM

#375137 RE: mrmainstreet #375135

mrmain, thanks for posting the SA story. I find it curious that the author even mentioned the Russian Oligarch Roman Abramovich and his investment in Sarissa he has not been sanctioned by the US so his investment in Sarissa is a nonissue.
icon url

ziploc_1

04/19/22 12:07 PM

#375143 RE: mrmainstreet #375135

MrMain...Good SA article, but it omits,as one of the positive points for Amarin, i.e. the important recent development of MD2119 in a potential once daily version of a statin-EPA combo drug.

A statin-EPA combo to be used four times a day is an improvement, but a once a day combo would be even better, especially for older patients, who need to take many drugs daily.
icon url

Birdbrain Ideas

04/19/22 3:32 PM

#375155 RE: mrmainstreet #375135

That Seeking Alpha article made some good points. It was sly on Amarin's part to take on a small California-based insurer. This way, it didn't cause an adverse reaction from the big insurers. Amarin knows that a victory against Health Net will ensure that insurance companies, big and small, take responsibility for the obvious infringement intent of the generics.

I'm not sure I would have claimed, as the author did, that two "courts" have ruled on the infringement case. It was really just two judges in the same court. A magistrate judge assigned by the district judge to do preliminary work and then the district judge himself.

The one surprise in the article to me was that the author didn't list among reasons why he'd pick up shares is an increase in sales in the U.S. and the beginning of meaningful sales in Europe and Canada. Seeing revenues growing by $100,000 or $200,000 each quarter and profits also on the increase would begin a steady rise in the share price.